Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.

Idemudia, O. (2025) Women’s Mental Health: Suicide Risks in Women with Premenstrual Dysphoric Disorder. Open Journal of ...

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...